Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)

Celebrations may be in order for Curis, Inc. (NASDAQ:CRIS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals.

Following the latest upgrade, Curis' five analysts currently expect revenues in 2025 to be US$11m, approximately in line with the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 38% to US$3.17. However, before this estimates update, the consensus had been expecting revenues of US$8.5m and US$4.19 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

Check out our latest analysis for Curis

earnings-and-revenue-growth
NasdaqCM:CRIS Earnings and Revenue Growth April 2nd 2025

The consensus price target fell 12%, to US$18.50, suggesting that the analysts remain pessimistic on the company, despite the improved earnings and revenue outlook.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. From these estimates it looks as though the analysts expect the years of declining sales to come to an end, given the flat revenue forecast out to 2025. That would be a definite improvement, given that the past five years have seen sales shrink 1.1% annually. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 19% per year. So it's pretty clear that, although revenues are improving, Curis is still expected to grow slower than the industry.

Advertisement

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Curis is moving incrementally towards profitability. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. A lower price target is not intuitively what we would expect from a company whose business prospects are improving - at least judging by these forecasts - but if the underlying fundamentals are strong, Curis could be one for the watch list.

These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 5 potential flags with Curis, including major dilution from new stock issuance in the past year. For more information, you can click through to our platform to learn more about this and the 3 other flags we've identified .

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqCM:CRIS

Curis

A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

Moderate risk with adequate balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
CNXU logo
Ceazar on Conexeu Sciences ·

This small biotech is developing technology that could potentially change how tissue is rebuilt

Fair Value:US$25.3461.2% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
PWR logo
HedgeY on Quanta Services ·

The Picks-and-Shovels Leader of the Grid Supercycle

Fair Value:US$7102.0% overvalued
11 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
FU
KRMN logo
FundamentalFlow on Karman Holdings ·

KRMN — Karman Space & Defense: Down 58% from Peak, Is the Market Mispricing a Hypergrowth Defense Compounder?

Fair Value:US$105.654.3% undervalued
6 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
IES logo
Double_Bubbler on Invinity Energy Systems ·

Invinity Energy Systems: All About That BESS

Fair Value:UK£163.7% undervalued
6 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

AC
ACV
RBLX logo
ACV on Roblox ·

Roblox Future PE to Soar by 17% in the Next 5 Years

Fair Value:US$21.48112.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TH
The_Markets_IQ
IXR logo
The_Markets_IQ on Ionic Rare Earths ·

IXR has a Plan to Bypass China's REE Separation Moat.

Fair Value:AU$0.8856.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
RockeTeller
IVR logo
RockeTeller on Investigator Silver ·

Investigator Silver, Leverage Exposed: $1/oz Move = $42M Cash for This ASX Developer

Fair Value:AU$2.3997.8% undervalued
17 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7445.3% undervalued
66 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1929.0% undervalued
51 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9721.9% undervalued
58 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative